The 2023 Bridgehead programme catalyst award winners
Antegenes (Estonia) has developed ground-breaking genetic tests to detect individual risks for the most common and deadly cancers worldwide, including breast, prostate, colorectal, and skin melanoma.
HMG Systems Engineering GmbH (Germany) has developed the PGXperts System, a Decision Support System designed to enable personalised medication, improve drug therapy safety, and deliver better patient welfare.
Micro-Cosmos (The Netherlands) helps hospitalised patients recover faster by reducing external stimuli improving sleep and rest. The Micro-Cosmos dome reduces sound and light, providing patients a secure and private environment.
OaCP IE LTD (Ireland) makes crucial DNA tests for cancer and infections faster and more accessible.
Osteobionix (Spain) has developed oBreathe, a patent-protected, clinically validated, patient-specific chest wall reconstruction implant, developed with ITC and skilled thoracic surgeons. This allows for physiologic breathing and restores shape and function.
Stroke2Prevent B.V. (The Netherlands) has developed A-View. This device enables clinicians to have real-time information resolving the blind spot during ultrasound imaging of the Aortic Arch and vessels and allowing them to tailor the surgical strategy to the best benefit of the patient.
InnoStars awards catalyst awardees 2023
NIB biotec srl (Italy) has developed ScreeNIB, a prostate cancer smart screening based on a smart biosensor that utilises urinary molecules as biomarkers for prostate cancer, offering a rapid and decentralised diagnostic solution outside hospitals.
Orgavalue (Portugal) by I-R3 Therapies aims to bioengineer personalised human livers to address the global organ transplant shortage.
IPLEXMED, LDA (Portugal) solution enables fast and reliable detection of multiple infectious agents and their drug resistance profile at point-of-care and home, empowering personalised treatment and real-time disease monitoring.
Breathing Solutions, Lda (Portugal) has developed eBreathie, a smart inhaler that turns traditional inhalers into “smart” devices, enabling patients and doctors to monitor medication usage and symptoms and provide personalised care remotely.
Nanodecal (Spain) has developed a rapid diagnostic test for detecting superbugs responsible for pneumonia in less than 10 minutes, aiding clinicians in prescribing targeted antibiotics and preventing permanent infections.
Reon sp. z o.o (Poland) has developed PeryView, a user-friendly web SaaS application that enables visual field testing at home, serving as a screening tool for detecting early symptoms of diseases such as glaucoma and neuropathies.